- 现金
- 176 元
- 精华
- 0
- 帖子
- 112
- 注册时间
- 2015-5-14
- 最后登录
- 2016-11-12
|
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073246.pdf
Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
High Dose Selection for General Toxicity Studies (1.5)
To support phase 3 clinical trials for the United States, dose-limiting toxicity generally should be identified in at least one species when using the 50-fold margin of exposure as the limit dose. If this is not the case, a study of 1 month or longer duration in one species that is conducted at the 1000 mg/kg limit dose, MFD or MTD, whichever is lowest, is recommended. However, on a case-by-case basis this study might not be warranted if a study of a shorter duration identifies dose-limiting toxicity at doses higher than those resulting in a 50-fold exposure margin.
这个观点的FDA文档原出处。自己判断。 |
|